Cargando…

LncRNA SRA1 may play a role in the uterine leiomyoma tumor growth regarding the MED12 mutation pattern

BACKGROUND: Uterine leiomyomas (ULMs) are benign uterine tumors that are estrogen-dependent. Recent studies suggest that the abnormal expression of the steroid receptor RNA activator 1 (SRA1) long non-coding RNA (lncRNA) might participate in the mechanisms of tumorigenesis of some hormone-dependent...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbari, Mojdeh, Yassaee, Fakhrolmolouk, Aminbeidokhti, Mona, Abedin-Do, Atieh, Mirfakhraie, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718952/
https://www.ncbi.nlm.nih.gov/pubmed/31507331
http://dx.doi.org/10.2147/IJWH.S211632
_version_ 1783447830282633216
author Akbari, Mojdeh
Yassaee, Fakhrolmolouk
Aminbeidokhti, Mona
Abedin-Do, Atieh
Mirfakhraie, Reza
author_facet Akbari, Mojdeh
Yassaee, Fakhrolmolouk
Aminbeidokhti, Mona
Abedin-Do, Atieh
Mirfakhraie, Reza
author_sort Akbari, Mojdeh
collection PubMed
description BACKGROUND: Uterine leiomyomas (ULMs) are benign uterine tumors that are estrogen-dependent. Recent studies suggest that the abnormal expression of the steroid receptor RNA activator 1 (SRA1) long non-coding RNA (lncRNA) might participate in the mechanisms of tumorigenesis of some hormone-dependent tumors including breast cancer. SRA1 is known to enhance the transcriptional activity of steroid receptors and also promotes steroidogenesis. The level of steroid hormones, such as estrogen and the progesterone, and their receptors play an important role in the development and growth of leiomyoma. The aim of the present study was to determine the expression level of lncRNA SRA1 in ULM tissues considering the MED12 mutation pattern. METHODS: Mutation screening was performed for MED12 exons 1 and 2 and the intronic flanking regions using Sanger sequencing in 60 ULM tissues. Quantitative real-time polymerase chain reaction (qRT-PCRs) was performed in order to estimate the expression of lncRNA SRA1 in leiomyoma samples with and without MED12 gene mutations. The expression results were analyzed by using LinReg and REST software. RESULTS: Mutations were detected in exon 2 of the MED12 in 28 (46.67%) ULM samples; including, 21 (75%) missense mutations and 7 (25%) in-frame deletions. No mutation was detected in the MED12 exon 1. LncRNA SRA1 was over-expressed in ULM samples without MED12 mutation compared with ULM samples harboring MED12 mutation (Expression ratio=2.5, P-value=0.004). CONCLUSION: Present results suggest that lncRNA SRA1 may explain the phenotypic difference observed in the tumor size of ULM samples considering MED12 mutation pattern. Therefore, it serves as a good therapeutic target and provides new insight into understanding the disease molecular mechanism.
format Online
Article
Text
id pubmed-6718952
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67189522019-09-10 LncRNA SRA1 may play a role in the uterine leiomyoma tumor growth regarding the MED12 mutation pattern Akbari, Mojdeh Yassaee, Fakhrolmolouk Aminbeidokhti, Mona Abedin-Do, Atieh Mirfakhraie, Reza Int J Womens Health Original Research BACKGROUND: Uterine leiomyomas (ULMs) are benign uterine tumors that are estrogen-dependent. Recent studies suggest that the abnormal expression of the steroid receptor RNA activator 1 (SRA1) long non-coding RNA (lncRNA) might participate in the mechanisms of tumorigenesis of some hormone-dependent tumors including breast cancer. SRA1 is known to enhance the transcriptional activity of steroid receptors and also promotes steroidogenesis. The level of steroid hormones, such as estrogen and the progesterone, and their receptors play an important role in the development and growth of leiomyoma. The aim of the present study was to determine the expression level of lncRNA SRA1 in ULM tissues considering the MED12 mutation pattern. METHODS: Mutation screening was performed for MED12 exons 1 and 2 and the intronic flanking regions using Sanger sequencing in 60 ULM tissues. Quantitative real-time polymerase chain reaction (qRT-PCRs) was performed in order to estimate the expression of lncRNA SRA1 in leiomyoma samples with and without MED12 gene mutations. The expression results were analyzed by using LinReg and REST software. RESULTS: Mutations were detected in exon 2 of the MED12 in 28 (46.67%) ULM samples; including, 21 (75%) missense mutations and 7 (25%) in-frame deletions. No mutation was detected in the MED12 exon 1. LncRNA SRA1 was over-expressed in ULM samples without MED12 mutation compared with ULM samples harboring MED12 mutation (Expression ratio=2.5, P-value=0.004). CONCLUSION: Present results suggest that lncRNA SRA1 may explain the phenotypic difference observed in the tumor size of ULM samples considering MED12 mutation pattern. Therefore, it serves as a good therapeutic target and provides new insight into understanding the disease molecular mechanism. Dove 2019-08-29 /pmc/articles/PMC6718952/ /pubmed/31507331 http://dx.doi.org/10.2147/IJWH.S211632 Text en © 2019 Akbari et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Akbari, Mojdeh
Yassaee, Fakhrolmolouk
Aminbeidokhti, Mona
Abedin-Do, Atieh
Mirfakhraie, Reza
LncRNA SRA1 may play a role in the uterine leiomyoma tumor growth regarding the MED12 mutation pattern
title LncRNA SRA1 may play a role in the uterine leiomyoma tumor growth regarding the MED12 mutation pattern
title_full LncRNA SRA1 may play a role in the uterine leiomyoma tumor growth regarding the MED12 mutation pattern
title_fullStr LncRNA SRA1 may play a role in the uterine leiomyoma tumor growth regarding the MED12 mutation pattern
title_full_unstemmed LncRNA SRA1 may play a role in the uterine leiomyoma tumor growth regarding the MED12 mutation pattern
title_short LncRNA SRA1 may play a role in the uterine leiomyoma tumor growth regarding the MED12 mutation pattern
title_sort lncrna sra1 may play a role in the uterine leiomyoma tumor growth regarding the med12 mutation pattern
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718952/
https://www.ncbi.nlm.nih.gov/pubmed/31507331
http://dx.doi.org/10.2147/IJWH.S211632
work_keys_str_mv AT akbarimojdeh lncrnasra1mayplayaroleintheuterineleiomyomatumorgrowthregardingthemed12mutationpattern
AT yassaeefakhrolmolouk lncrnasra1mayplayaroleintheuterineleiomyomatumorgrowthregardingthemed12mutationpattern
AT aminbeidokhtimona lncrnasra1mayplayaroleintheuterineleiomyomatumorgrowthregardingthemed12mutationpattern
AT abedindoatieh lncrnasra1mayplayaroleintheuterineleiomyomatumorgrowthregardingthemed12mutationpattern
AT mirfakhraiereza lncrnasra1mayplayaroleintheuterineleiomyomatumorgrowthregardingthemed12mutationpattern